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IntroductIon
According to the European Medicines Agency (EMA), a biosimilar drug is a version of an 
already registered original product, the reference product (RP), whose qualitative characteris-
tics, biological activity, and safety and efficacy profiles have been shown to be similar to those 
of the RP by means of comparability studies [1]. The first-generation biologics were launched 
in the early 1980s, and this innovative class of drugs is now one of the fastest growing sectors 
of the pharmaceutical industry [2].
Biosimilars and reference drugs cannot be considered to be totally equivalent since, even 
after patent expiration, the reference agent manufacturer is not obliged to reveal details of its 
production practice [3]. Furthermore, biologicals are produced using living cells that have 
inherent variability, hence they are complex mixtures of closely related molecules that cannot 
be copied exactly. Similarity to the RP is demonstrated in a comprehensive biosimilarity exer-
cise including comparative physicochemical characterization, biological activity assessment, 
pharmacokinetic studies and clinical trials. A biosimilar may be approved by the EMA based 
on clinical data in a sensitive indication; efficacy and safety data may be extrapolated to other 
indications approved for the RP, meaning that a biosimilar agent may not have been clinically 
tested in each indication [1,4].
The EMA’s assessment of biosimilar medicines is done exclusively for the purpose of 
marketing authorization; Any decision to transition a patient from RP to biosimilar should 
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AbstrAct
INTRODUCTION: Anti-TNF-α biosimilars (ATB) hold the promise of reducing costs leading in improving access to bio-
logical therapies. There is limited insight into how the savings generated by biosimilars may translate into patient benefit 
in other disease areas.
AIMS: To assess the economic savings for Italian National Health System (NHS) due to the expansion of ATB market, 
together with a reduction in their price and to illustrate how this potential savings can be used by NHS to fund orphan drugs.
METHODS: Trend of IMS Health monthly sell-in units (August 2016-December 2019) were used to estimate the current 
biologic and biosimilar market for rheumatic and inflammatory bowel disease in Italy and its evolution up to 2022. The 
scenario for 2019-2020 was compared with the future evolution (2021-2022) assuming an increasing uptake of biosimilars 
in the Italian market. Finally, it was estimated how these savings can potentially fund the treatment of orphan drugs, without 
increasing the Italian NHS budget.
RESULTS: Italian biologic and biosimilar market remains stable in the next years (about 4 million units both in the current 
scenario and in the future evolution market) with a slight decreasing of less than 2%. However, according to our assump-
tions, ATB market is expected to increase of about 33% in the next two years, covering 67% of the total Italian market, 
mostly due to biosimilar etanercept. Total savings due to biosimilars increases from € 96 million in 2019 to € 161 million 
in 2022 corresponding to a mean annual savings of about € 130 million. Such savings would permit funding 17.4% of the 
actual orphan drugs market corresponding to 2,600-4,800 new patients.
CONCLUSIONS: The introduction of biosimilars in a range of rheumatic, dermatological and inflammatory bowel disease 
can be an opportunity to increase patient access to innovative treatments. Potential savings due to biosimilars uptake could 
lead to a re-allocation of economic resources to fund innovative therapies.
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be made by qualified healthcare personnel on the basis of national or local guidelines [5]. 
The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) considers biosimilars 
and RP as interchangeable products (i.e. they are assumed to have the same effectiveness 
and they can be used for the same disease), both for naïve patients and for patients already 
under treatment, but recommends that the decision to prescribe a biosimilar drug be made 
exclusively by the specialist managing the specific disease [6]. Clinicians must thus be aware 
of the availability of a biosimilar and they must be free to make informed treatment choices 
with their patients.
As of the end of 2019, there are ten approved anti-TNF-α biosimilar (ATB) medicines 
that are available on the Italian market. Three biosimilar versions of infliximab, one of which 
is available under two brand names, Inflectra® and Remsima® (manufactured by Celltrion 
Inc.), one under the brand name Flixabi® (manufactured by Biogen), and one under the brand 
name Zessly® (manufactured by Sandoz). All biosimilars are approved for use in rheumatoid 
arthritis (RA), adult and pediatric Crohn’s disease (CD), adult and pediatric ulcerative colitis 
(UC), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis [7-9]. Two etan-
ercept biosimilars are available under the brand name Benepali® (manufactured by Biogen) 
and Erelzi® (manufactured by Sandoz). Both biosimilars are approved for the treatment of 
adults with RA, PsA, axial spondyloarthritis (AS and non-radiographic axial spondyloarthri-
tis), juvenile idiopathic arthritis (JIA), and plaque psoriasis including pediatric in patients 
weighing >62.5 kg [10,11]. Finally, five adalimumab biosimilars have been approved in Eu-
rope for use in mostly the same indications as reference adalimumab including rheumatol-
ogy, gastroenterology and dermatology: Amgevita® (Amgen), Imraldi® (Biogen), Hyrimoz® 
(Sandoz), Hulio® (Mylan) and Idacio® (Fresenius Kabi). Amgevita® and Imraldi® are reim-
bursed in Italy since the end of 2018, Hyrimoz and Hulio during 2019, while Idacio has not 
yet been reimbursed [12-16].
Switching between a RP and a ATB is relevant for clinical practice, but also for pharmaco-
economic considerations; the arrival of ATB is expected to provide cost savings and expand 
access to other medicinal products [17]. While there is continued debate about interchange-
ability of biosimilars, recent systematic reviews concluded that there was no increased risk 
of immunogenicity or adverse events, and no significant loss of efficacy or effectiveness was 
observed [18-21]. According to another comprehensive systematic review of published evi-
dence summarizing all of the available studies (up to September 2015) on biosimilars across 
multiple therapeutic areas and at all stages of development [22], both Inflectra® and Flixabi® 
are reported to have shown evidence of similarity with their originator, based on results of 
clinical studies as well as a large number of patients described in real-world studies.
The NOR-SWITCH study [23], involved 481 adult patients with a diagnosis of RA, AS, 
PsA, CD, UC or plaque psoriasis, on stable treatment with the originator infliximab (Remi-
cade®) for at least 6 months prior to randomization; patients were randomized to continue 
RP, or switch to CT-P13 (Inflectra®/Remsima®) and followed for 52 weeks, clinical outcomes 
were comparable between the two arms. Furthermore real-word studies [24,25] and results 
from PLANETAS and PLANETRA extension studies [26,27], showed analogous results for 
infliximab biosimilars for patients with RA and AS.
In an open-label extension to the phase III, 52-week randomized study that compared 
etanercept biosimilar SB4 (Benepali®) with reference etanercept (Enbrel®) for the treatment 
of RA, 126 patients continued to receive ATB and 119 patients switched from reference etan-
ercept to SB4 for a further 48 weeks [28]. At the end of this open-label treatment period, the 
efficacy, safety and immunogenicity profiles were comparable for both groups. A real-world 
study, evaluating the safety and effectiveness of switching from Enbrel® to Benepali® in pa-
tients with RA, PsA or axial spondyloarthritis [29] reported no clinically relevant difference in 
disease activity at 3 months post-switch, nor in that observed in the 3 months prior to switch.
Inotai et al. [30] conducted a systematic literature review to assess the clinical consequenc-
es of switching from originator biologics to biosimilar. The analysis identified 58 papers: 41 
non-empirical papers (15 not disease specific, 9 on IBD, 5 on RA, 5 on chronic kidney dis-
ease and anemia, and 3 focused on malignancies), 5 systematic reviews (3 on infliximab and 
related ATB in inflammatory diseases, and 2 no drug-specific) and 12 original clinical studies 
(4 on IBD, 4 on chronic kidney disease and anemia, 2 on RA, and 1 on AS). None of the 5 
systematic reviews concluded that there were safety or efficacy concerns in switching from 
the original biologics to biosimilars, and 3 of them also explicitly stated that switching from 
an original biologic to a biosimilar drug was not associated with increased safety risk, while 
effectiveness was maintained. Also, two trials explicitly reported no adverse events or loss of 
efficacy related to switching, whereas 10 trials concluded that, overall, there was no increased 
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risk of immunogenicity or adverse events, while no statistically significant loss of efficacy 
was observed. In conclusion, the opinion of the authors of this review is that the fear against 
switching to biosimilars is not supported by empirical evidence.
The last position paper on ATB published in Italy by AIFA [6], confirmed this statement 
and highlighted the importance of ATB in improving the accessibility to biological therapies 
due to high cost of RP. Use of biosimilars in the EU5 countries alone stands to offer savings 
of more than € 10 billion between 2016 and 2020 [31]. Expanding ATB market could finance 
other therapeutic area, partially or completely.
Aims of this paper are
 - To assess the economic savings for Italian National Health System (NHS) due to the ex-
pansion of ATB market, together with a reduction in their price,
 - To illustrate how this potential savings can be used by NHS to fund orphan drugs.
Methods
The anti-TNF-α market evolution in Italy was estimated using monthly sell-in units be-
tween January to December 2019 [32], applying an annual increasing rate estimated from Au-
gust 2018 to December 2019 and supposed constant up to 2022 (Table I). Only formulations 
available both as RP and ATB were considered in the analysis, e.g. Enbrel® (etanercept) 10 
mg is excluded from the analysis since not available as biosimilar. Annual ATB uptake was as-
sumed almost linear from 2019 to 2022 for all treatments considered in the analysis according 
to Biogen internal analysis (Figure 1). Current market was defined as biennium 2019-2020, 
future market as biennium 2021-2022.
Only drug acquisition cost was considered in the analysis since, as described in the intro-
duction, no evidence of lower efficacy or increased toxicity with or after switching to an ATB 
were detected in clinical trials or real-world studies. The ex-factory reimbursement price [33] 
charged to NHS, net of price reductions stipulated by law and by tender procedures [34] was 
considered for all available products (Table II).
rP/ATB Actual Market (2019 sell-in units) Annual increasing (2020-2022)
Adalimumab (40 mg syringes/pens) 734,853 +7.1%
Etanercept (25 mg syringes/pens) 114,687 -4.3%
Etanercept (50 mg syringes/pens) 812,085 -9.1%
Infliximab (100 mg vials) 277,489 -2.5%
Table I. Italian biologic and ATB market for 2019 (number of unit sold between January and December) and 2020-2022 evolution
ATB = anti-TNF-α biosimilars; RP = reference products
Figure 1. Italian anti-TNF-α biosimilars uptake for 2019-2022
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The savings generated by all ATB available in the Italian market was calculated as the dif-
ference between the actual market (Table I) and the hypothetical market with all ATB replaced 
by the corresponding RP. Finally, a simulation estimated how these savings can potentially 
fund innovative treatments for orphan diseases.
The current model of attribution of the degree of innovation defined by AIFA [35] is based 
on three domains: the therapeutic need (TN), the added therapeutic value (ATV), and the qual-
ity of the evidence (QE) carried to support the drug. The first two factors are graded in five 
levels (maximum, important, moderate, poor, absent), the third factor is evaluated as high, 
moderate, low, very low. A drug is declared innovative if QE is “high” and both TN and ATV 
are valued “maximum” or “important”. For rare diseases, a greater difficulty in conducting 
clinical trials is acknowledged, which is why is it possible to consider innovative a drug with 
low QE, provided TN and ATV are high [35].
All orphan drugs, that were granted the innovative status up to end of January 2019 [36] 
were included in the analysis (Table III).
The economic impact of each drug was calculated by estimating the annual number of 
new patients that should be treated with each drug and the cost of the first year of treatment 
[37-49]. According to the savings produced by ATB uptake, a percentage of this impact could 
be funded, i.e. a fraction of patients could be treated without increasing the NHS budget. Two 
potential allocation algorithms, depending on the policy preferred by the decision-makers, 
were considered:
 - Cost allocation proportional to number of potential new patients; i.e. the higher the disease 
incidence, the higher the fraction of resources dedicated to that disease;
 - Optimal allocation calculated in order to globally maximize the fraction of patients (across 
diseases) potentially treated without increasing NHS expenditures.
results
Evolution of the Italian biologic and biosimilar market due to increasing use of ATB is 
illustrated in Figure 2. Italian market remains basically stable in the next years: 3.85 million 
units in the current market (2019-2020) compared with 3.80 million in the future evolution 
market (2021-2022), corresponding to a slight decreasing of about 1.4% (Table IV). However, 
according to our assumptions, ATB market is expected to increase of 33% up to 2022, cover-
ing 67% of the total Italian market, mostly due to adalimumab (38%) and etanercept (44%) 
biosimilars uptake.
The economic impact of ATB uptake in Italy is detailed in Table V. Total savings due to 
ATB increases from € 96.2 million in 2019 to € 161.5 million in 2022 (mean annual savings 
€ 128.8 million). Comparing 2019-2020 market with future evolution in the total savings 
amount to about € 84 million.
The number of new patients potentially treated for selected orphan diseases ranges be-
tween 15 for autologous CD34+ cells to almost 9,700 for cenegermin in Italy (Table VI). 
Drug Branded Pharmaceutical form Ex-factory price (€)
Adalimumab Humira® 40 mg solution for injection in pre-filled syringe 482.19
Imraldi® 342,35
Amgevita® 342,35
Hyrimoz® 342,35
Etanercept Enbrel® 25 mg solution for injection in pre-filled syringe 115.13
50 mg solution for injection in pre-filled syringe 230.26
Benepali® 25 mg solution for injection in pre-filled syringe 78.52
50 mg solution for injection in pre-filled syringe 157.25
Erelzi® 25 mg solution for injection in pre-filled syringe 74.84
50 mg solution for injection in pre-filled syringe 149.67
Infliximab Remicade® 100 mg powder for concentrate for solution for infusion 463.53
Flixabi® 386.28
Inflectra® 386.28
Remsima® 386.28
Zessly® 386.28
Table II. Ex-factory prices in Italy
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The savings generated by all ATB available in the Italian market was calculated as the dif-
ference between the actual market (Table I) and the hypothetical market with all ATB replaced 
by the corresponding RP. Finally, a simulation estimated how these savings can potentially 
fund innovative treatments for orphan diseases.
The current model of attribution of the degree of innovation defined by AIFA [35] is based 
on three domains: the therapeutic need (TN), the added therapeutic value (ATV), and the qual-
ity of the evidence (QE) carried to support the drug. The first two factors are graded in five 
levels (maximum, important, moderate, poor, absent), the third factor is evaluated as high, 
moderate, low, very low. A drug is declared innovative if QE is “high” and both TN and ATV 
are valued “maximum” or “important”. For rare diseases, a greater difficulty in conducting 
clinical trials is acknowledged, which is why is it possible to consider innovative a drug with 
low QE, provided TN and ATV are high [35].
All orphan drugs, that were granted the innovative status up to end of January 2019 [36] 
were included in the analysis (Table III).
The economic impact of each drug was calculated by estimating the annual number of 
new patients that should be treated with each drug and the cost of the first year of treatment 
[37-49]. According to the savings produced by ATB uptake, a percentage of this impact could 
be funded, i.e. a fraction of patients could be treated without increasing the NHS budget. Two 
potential allocation algorithms, depending on the policy preferred by the decision-makers, 
were considered:
 - Cost allocation proportional to number of potential new patients; i.e. the higher the disease 
incidence, the higher the fraction of resources dedicated to that disease;
 - Optimal allocation calculated in order to globally maximize the fraction of patients (across 
diseases) potentially treated without increasing NHS expenditures.
results
Evolution of the Italian biologic and biosimilar market due to increasing use of ATB is 
illustrated in Figure 2. Italian market remains basically stable in the next years: 3.85 million 
units in the current market (2019-2020) compared with 3.80 million in the future evolution 
market (2021-2022), corresponding to a slight decreasing of about 1.4% (Table IV). However, 
according to our assumptions, ATB market is expected to increase of 33% up to 2022, cover-
ing 67% of the total Italian market, mostly due to adalimumab (38%) and etanercept (44%) 
biosimilars uptake.
The economic impact of ATB uptake in Italy is detailed in Table V. Total savings due to 
ATB increases from € 96.2 million in 2019 to € 161.5 million in 2022 (mean annual savings 
€ 128.8 million). Comparing 2019-2020 market with future evolution in the total savings 
amount to about € 84 million.
The number of new patients potentially treated for selected orphan diseases ranges be-
tween 15 for autologous CD34+ cells to almost 9,700 for cenegermin in Italy (Table VI). 
Drug Branded Pharmaceutical form Ex-factory price (€)
Adalimumab Humira® 40 mg solution for injection in pre-filled syringe 482.19
Imraldi® 342,35
Amgevita® 342,35
Hyrimoz® 342,35
Etanercept Enbrel® 25 mg solution for injection in pre-filled syringe 115.13
50 mg solution for injection in pre-filled syringe 230.26
Benepali® 25 mg solution for injection in pre-filled syringe 78.52
50 mg solution for injection in pre-filled syringe 157.25
Erelzi® 25 mg solution for injection in pre-filled syringe 74.84
50 mg solution for injection in pre-filled syringe 149.67
Infliximab Remicade® 100 mg powder for concentrate for solution for infusion 463.53
Flixabi® 386.28
Inflectra® 386.28
Remsima® 386.28
Zessly® 386.28
Table II. Ex-factory prices in Italy
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Funding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy
Different allocation strategies gave different consequences on the number of patients treated 
without impacting NHS expenditures: with strategy 1 (cost allocation proportional to disease 
incidence), 4,837 new patients can be funded by ATB saving where the proportions of patients 
treated for each disease result very different (Table VI and Figure 3); with strategy 2 (optimal 
allocation) instead, the fraction of patients treated without impacting NHS results around 14-
18%, but the total number of patients decreases down to 2,640 (Table VI and Figure 3).
dIscussIon
In this analysis we estimated the total pharmaceutical impact of ATB in the 2019 Italian 
market and its evolution in the next three years due to increasing ATB. Biosimilars market 
Figure 2. Resulting Italian market for 2019-2022
2019-2020 2021-2022
Italian market (total biologic and biosimilar sell-in units) 3,854,311 3,801,377
ATB market, units (%) 1,914,379 (50%) 2,554,607 (67%)
Adalimumab, units (%) 535,192 (28%) 962,521 (38%)
Etanercept, units (%) 954,678 (50%) 1,123,802 (44%)
Infliximab, units (%) 424,509 (22%) 468,284 (18%)
Table IV. Comparison between 2019-2020 Italian market and evolution estimated for 2021-2022
ATB = anti-TNF-α biosimilars
Current market Future market evolution
2019 2020 2021 2022
Annual drug cost – market without ATB (€) 612,683,002 617,038,368 624,426,997 634,832,963
Annual drug cost – market with ATB (€) 516,465,296 497,648,431 486,202,672 473,365,303
Savings due to ATB (€) 96,217,706 119,389,937 138,224,325 161,467,660
Mean annual saving due to ATB (€) 128,824,907
Increase in total savings due to ATB – future vs current market (€) 84,084,342
Table V. Economic impact of ATB market increasing in Italy
ATB: anti-TNF-α biosimilars
Drug
New 
patients  
(n/year)
Therapy 
cost  
(€/year)
strategy 1: Cost allocation 
proportional to disease incidence
strategy 2: Optimal 
allocationa
savings 
allocation (%)
New patients 
potentially 
treated (n)
savings 
allocation 
(%)
New patients 
potentially 
treated (n)
Daratumumab (Darzalex®) 5,197 92,982 32.7 453 69.2 959
Cenegermin (Oxervate®) 9,658 18,957 60.8 4,132 22.5 1,532
Letermovir (Prevymis®) 574 30,000 3.6 155 1.9 83
Dinutuximab beta (Qarziba®) 135 149,515 0.8 7 2.3 20
Midostaurina (Rydapt®) 231 21,485 1.5 87 0.6 33
Nusinersen (Spinraza®) 73 302,400 0.5 2 2.5 11
Autologous cd34+ cells 
(Strimvelis®)
15 594,000 0.1 <1 1.0 2
Total 15,883 739,677,228 100 4,837 100 2,640
Mean annual savings 
due to ATB (€/year)
128,824,907
Table VI. New patients potentially treated without impact on NHS due to ATB savingsa Optimal allocation was defined as the resources 
allocation that permits to fund the maximal percentage of patients globally (i.e. for all diseases considered in the analysis)
ATB = anti-TNF-α biosimilars
Figure 3. Percentage of new patients potentially treated without impact on NHS due to ATB savings (comparison between allocation 
proportional to patients and optimal allocation)
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grows, from 50% (current market 2019-2020) to 67% (future market 2021-2022), produces 
an increasing trend in the annual savings from about € 96 million in 2019 up to € 161 million 
in 2022. In line with the AIFA position, this favorable impact on NHS expenditures could be 
directed to fund innovation, in particular to fund more expensive therapeutic areas, such as 
orphan drugs gained innovative status.
Our estimate may be too conservative since the biosimilar market is rapidly evolving, both 
due to increase in biosimilars price discounting and biosimilars uptake; this evolution could 
lead to greater savings.
The cost analysis by Mulcahy et al. [50] for US estimated that the total biosimilar market 
(including all available biologic classes) is expected to save approximately $ 44 billion from 
2014 to 2024; this savings is due mainly to ATB that account for 21% of the estimated savings.
Jha et al. [51] estimated the impact of Remsima® for the treatment of autoimmune diseases 
in five European Countries (Germany, UK, Italy, The Netherlands and Belgium). Under the 
assumption that the list price of Remsima® might be between 10% and 30% lower than the 
current list price of Remicade®, ATB uptake resulted to be associated with considerable drug 
Different allocation strategies gave different consequences on the number of patients treated 
without impacting NHS expenditures: with strategy 1 (cost allocation proportional to disease 
incidence), 4,837 new patients can be funded by ATB saving where the proportions of patients 
treated for each disease result very different (Table VI and Figure 3); with strategy 2 (optimal 
allocation) instead, the fraction of patients treated without impacting NHS results around 14-
18%, but the total number of patients decreases down to 2,640 (Table VI and Figure 3).
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128,824,907
Table VI. New patients potentially treated without impact on NHS due to ATB savingsa Optimal allocation was defined as the resources 
allocation that permits to fund the maximal percentage of patients globally (i.e. for all diseases considered in the analysis)
ATB = anti-TNF-α biosimilars
Figure 3. Percentage of new patients potentially treated without impact on NHS due to ATB savings (comparison between allocation 
proportional to patients and optimal allocation)
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cost savings for the healthcare payer for all countries; in Italy the savings ranged between € 
4.6 to € 13.8 Million during the first year after launch.
ATB savings could be used to fund other therapeutic areas. In this analysis, such savings 
was converted in new patients potentially treated without impact on NHS. Orphan drugs were 
chosen since the correspondent disease costs are significantly high; according to epidemiol-
ogy and drugs posology, this impact is estimated in about 740 million per year (Table VI). 
The annual savings due to ATB uptake could finance 17.4% of this cost; depending on the 
decision of the policy makers, favoring equal access across diseases, or rather assigning freed 
resources proportionally to their incidence in the population, this corresponds to about 2,600-
4,800 new patients affected by orphan diseases treated with innovative drugs, without increas-
ing overall NHS expenditures.
conclusIon
The introduction of biosimilars in a range of rheumatic, dermatological and inflammatory 
bowel disease can be an opportunity to increase patient access to innovative treatments. Po-
tential savings due to biosimilars uptake could lead to a re-allocation of economic resources 
to fund innovative therapies.
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